Allergan Specialty Therapeutics Inc.
The Irvine pharmaceutical research and development company said it lost $15.1 million, or $4.61 a share, for the second quarter, compared with a loss of $12.2 million, or $3.72 a share, for last year’s second quarter. Revenue, consisting of interest and investment income, was $861,000, down from the $2.3 million posted a year ago.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
